• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

KL1333, orphan drug approved for the treatment of mitochondrial disorders


Senior Member
Midwest USA
“KL1333 is a potent regulator of the cellular levels of NAD+, a key molecule in the cell’s energy metabolism. In preclinical studies, KL1333 was able to increase mitochondrial energy levels, reduce the formation and accumulation of toxic compounds (e.g., lactate and free radicals), and induce the formation of new mitochondria.”



Senior Member
Awesome! Looking forward to put my hands on this when available.
A pre-clinical study is a long way from proof that this stuff is effective for the treatment of any disease, much less one one understands. Hope it pans out, don’t hold your breath.